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Background: The incidence of invasive fungal infections has
increased worldwide with Candida species causing the majority of
these. Increasing resistance to antifungal agents has beendescribed
and contributes to the difﬁculty in treating these infections. Hence,
rapid yeast identiﬁcation and susceptibility testing methods that
will facilitate prompt initiation of appropriate therapy are required
to optimize patient management.
The Vitek® 2 antifungal susceptibility testing system
(bioMerieux) is a fully automated commercial method that
allows both fungal identiﬁcation and MIC determination simulta-
neously within 24hours, compared to the manual API® and Etest®
(bioMerieux) methods.
Methods&Materials: 60 routine positive yeast culture isolates,
from different sites that had been processed for fungal identi-
ﬁcation and susceptibility testing, using the standard laboratory
method were tested on the Vitek 2 system according to the man-
ufacturer’s instructions. The Vitek® 2 YST and Vitek® 2 AST-YS07
cardswereused for identiﬁcationand susceptibility testing, respec-
tively.
Results: All of the Vitek® 2 results were available within
24hours. There was a 98% concordance with the identiﬁcation
results and 100% concordance with susceptibility test results
between the two methods. All discordant samples were retested
using the Vitek® MS MALDI-TOF identiﬁcation method, and these
were found to be in agreement with the Vitek® 2. The instrument
was found to be easy to use and required minimal maintenance.
Conclusion: The adoption of this fully automated fungal iden-
tiﬁcation and susceptibility testing system in the laboratory will
signiﬁcantly impact on patient management and outcomes as it
reduces technologist hands-on time, turnaround times, and vari-
ability in patient results by using a standardized format.
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Background: In sub-Saharan Africa, an estimated 20% of all
cases of active pulmonary TB occur in children.
Currently available diagnostic techniques (i.e smearmicroscopy
and culture) are inadequate for rapid and accurate detection of
Mycobacterium tuberculosis in children.
TheXpertMTB/RIFassay isonlyvalidated for sputumspecimens,
thus limiting its use in the diagnosis of TB to patients who are able
to expectorate sputum.
A large proportion of paediatric patients are unable to expecto-
rate sputum and clinicians have to resort to alternative specimens
such as gastric aspirates for TB investigations.
The purpose of this study was to evaluate the Xpert MTB/RIF
assay for the detection ofMycobacterium tuberculosis complex from
nasogastric aspirate specimens in paediatric patients.
Methods & Materials: Eighty six remnant nasogastric spec-
imens from paediatric patients with a volume of ≥ 2ml were
collected from the National Health Laboratory Services (NHLS)
TB Laboratory. The specimens were split into 2 aliquots, one for
microscopy and M. tuberculosis liquid culture with MGIT 960 (Bec-
ton Dickinson) and the other for Xpert MTB/RIF assay (Cepheid).
All culture positives were further identiﬁed with the GenoType
MTBDRplus V 2.0(Hain Lifescience).
Results: None of the specimens were positive by smear
microscopy.
Seven (7/86) specimens were positive for Mycobacterium tuber-
culosis.
The Xpert MTB/RIF assay detected 5/7 culture positive speci-
menswith an additional four specimens thatwere culture negative.
The Xpert MTB/RIF assay did not detect Rifampicin resistance in
six (6/9) specimens, however, three (3/9) were Rifampicin indeter-
minate.
All 7 culture positive isolates tested sensitive for Rifampicin by
the GenoType MTBDRplus assay.
The sensitivity and speciﬁcity values of the XpertMTB/RIF assay
was determined to be 71% and 94% respectively.
Conclusion: Study ﬁndings suggest that the Xpert MTB/RIF
assay can be useful in rapid detection ofMycobacterium tuberculosis
from nasogastric aspirate specimens in the paediatric population
and these specimens can be used as an alternative to sputum in
children unable to expectorate.
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